학술논문
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Document Type
Article
Author
Goepfert, Paul A; Fu, Bo; Chabanon, Anne-Laure; Bonaparte, Matthew I; Davis, Matthew G; Essink, Brandon J; Frank, Ian; Haney, Owen; Janosczyk, Helene; Keefer, Michael C; Koutsoukos, Marguerite; Kimmel, Murray A; Masotti, Roger; Savarino, Stephen J; Schuerman, Lode; Schwartz, Howard; Sher, Lawrence D; Smith, Jon; Tavares-Da-Silva, Fernanda; Gurunathan, Sanjay; DiazGranados, Carlos A; de Bruyn, Guy
Source
In The Lancet Infectious Diseases September 2021 21(9):1257-1270
Subject
Language
ISSN
1473-3099